SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB AS A TREATMENT IN PATIENTS WITH EARLY HER 2 POSITIVE BREAST CANCER : EXPERIENCE OF A CANCER CENTER IN PERU

被引：0
|
作者：
Otoya, Iris
Valdivieso, Natalia
Morante, Zaida
Castaneda, Carlos
Neciosup, Silvia
Calderon, Monica
Gomez, Henry
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-17-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-17-08
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [22] Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
    Piezzo, Michela
    D'Aniello, Roberta
    Avallone, Ilaria
    Barba, Bruno
    Cianniello, Daniela
    Cocco, Stefania
    D'Avino, Antonio
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Piscitelli, Raffaele
    von Arx, Claudia
    De Laurentiis, Michelino
    Maiolino, Piera
    PHARMACEUTICS, 2021, 13 (05)
  • [23] Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label randomized, multicenter, phase IIIB ESCAPE trial
    Kaidarova, Dilyara
    Zhavrid, Edvard
    Shatkovskaya, Oxana
    Prokharau, Aliaksandr
    Akhmed, Nina
    Sembayev, Dauren
    Rutzhanova, Zhanna
    Ivankov, Alexandr
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40
  • [24] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Denys, Hannelore
    Martinez-Mena, Corina L.
    Martens, Marc T.
    D'Hondt, Randal G.
    Graas, Marie-Pascale L.
    Evron, Ella
    Fried, Georgeta
    Ben-Baruch, Noa E.
    Vulsteke, Christof
    Van Steenberghe, Mona M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 97 - 105
  • [25] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Hannelore Denys
    Corina L. Martinez-Mena
    Marc T. Martens
    Randal G. D’Hondt
    Marie-Pascale L. Graas
    Ella Evron
    Georgeta Fried
    Noa E. Ben-Baruch
    Christof Vulsteke
    Mona M. Van Steenberghe
    Breast Cancer Research and Treatment, 2020, 181 : 97 - 105
  • [26] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [27] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [28] Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland
    O'Brien, Gary L.
    O'Mahony, Cian
    Cooke, Katie
    Kinneally, Ada
    Sinnott, Sarah-Jo
    Walshe, Valerie
    Mulcahy, Mark
    Byrne, Stephen
    CLINICAL BREAST CANCER, 2019, 19 (03) : E440 - E451
  • [29] Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
    G. Lopez-Vivanco
    J. Salvador
    R. Diez
    D. López
    M. De Salas-Cansado
    B. Navarro
    J. De la Haba-Rodríguez
    Clinical and Translational Oncology, 2017, 19 : 1454 - 1461
  • [30] Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
    Lopez-Vivanco, G.
    Salvador, J.
    Diez, R.
    Lopez, D.
    De Salas-Cansado, M.
    Navarro, B.
    De la Haba-Rodriguez, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12): : 1454 - 1461
12345